European Commission Expands Merck's VAXNEUVANCE Indication to Include Infants, Children and Adolescents Life Science Investing
Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living With HIV With a Range of Comorbidities Pharmaceutical Investing
Merck's PREVYMIS Demonstrates Efficacy in Phase 3 Study for Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation Life Science Investing
BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing Pharmaceutical Investing
U.S. Food and Drug Administration Accepts Supplemental New Drug Application for CAMZYOS® in Symptomatic Obstructive Hypertrophic Cardiomyopathy to Reduce the Need for Septal Reduction Therapy Pharmaceutical Investing
Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers Pharmaceutical Investing
AbbVie's SKYRIZI® Receives Health Canada Approval as the First and Only Specific Interleukin-23 to Treat Moderately to Severely Active Crohn's Disease in Adults Pharmaceutical Investing
Albert Labs Files New International PCT Patent Application for scalable API manufacturing Pharmaceutical Investing
Ortho Dermatologics To Present New Data at the 2022 Fall Clinical Dermatology Conference Pharmaceutical Investing
